Gujarat Kidney and Super Speciality Updates IPO Fund Allocation

Original Vadodara hospital budget: Rs 30.10 Cr; Revised allocation: Rs 17.92 Cr.

Reader Takeaway: Investors gain clarity on capital shifts toward international expansion, though original infrastructure project scope is reduced.

What just happened

Gujarat Kidney and Super Speciality Ltd has filed its Statement of Deviation and Variation for the quarter ended September 30, 2026. The company, which raised Rs 250.80 Cr in its December 2025 IPO, has officially adjusted the utilization of funds originally earmarked for a new hospital facility in Vadodara. The change was approved by shareholders via a special resolution in August 2026.

Why this matters

The company has diverted Rs 12.18 Cr from the initial Rs 30.10 Cr set for the Vadodara hospital. The new objective covers broader healthcare expansion, specifically the acquisition of a 51% stake in Blue Tree Clinics LLC in Dubai, UAE. Of the newly allocated Rs 17.92 Cr for this updated objective, Rs 7.23 Cr has already been utilized.

The backstory

The IPO, launched in December 2025, outlined multiple growth objectives. While several core projects—including the acquisition of Parekh Hospital in Ahmedabad and stakes in Harmony Medicare—have seen full utilization of funds, the Vadodara hospital project underwent a scope modification to accommodate strategic inorganic growth in the Middle East.

Risks to watch

Investors should monitor the integration success of the newly acquired UAE-based Blue Tree Clinics. Additionally, while other IPO objects remain on track or fully utilized, any further changes to capital allocation plans may impact the originally promised infrastructure timelines.

Context metrics

The Audit Committee reviewed these changes on November 4, 2026, finding no discrepancies or negative remarks from auditors. General corporate purposes and inorganic growth funds totaling Rs 87.44 Cr have been fully utilized, indicating the company is aggressively pursuing its expansion roadmap.